

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT8334153

| | |
|---|--|
| SUBMISSION TYPE: | NEW ASSIGNMENT |
| NATURE OF CONVEYANCE: | ASSIGNMENT |
| CONVEYING PARTY DATA | |
| Name | Execution Date |
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | 11/22/2023 |
| RECEIVING PARTY DATA | |
| Name: | SCOHIA PHARMA, INC. |
| Street Address: | 26-1, MURAOKA-HIGASHI 2-CHOME, FUJISAWA-SHI, |
| City: | KANAGAWA |
| State/Country: | JAPAN |
| Postal Code: | 251-8555 |
| PROPERTY NUMBERS Total: 1 | |
| Property Type | Number |
| Patent Number: | 10087229 |
| CORRESPONDENCE DATA | |
| Fax Number: | (202)721-8250 |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> | |
| Phone: | 12027218200 |
| Email: | wlp@wenderoth.com |
| Correspondent Name: | WENDEROTH, LIND & PONACK, LLP |
| Address Line 1: | 1025 CONNECTICUT AVENUE, N.W. |
| Address Line 2: | SUITE 500 |
| Address Line 4: | WASHINGTON, D.C. 20036 |
| ATTORNEY DOCKET NUMBER: | 2015-0889A |
| NAME OF SUBMITTER: | KELLY J. FORE |
| SIGNATURE: | /Kelly J. Fore/ |
| DATE SIGNED: | 12/15/2023 |
| Total Attachments: 1 | |
| source=ASSIGNMENT DOC#page1.tif | |

ASSIGNMENT

In consideration of the payment by ASSIGNEES to ASSIGNOR of the sum of One Dollar (\$1.00), the receipt of which is hereby acknowledged, and for other good and valuable consideration,

ASSIGNOR: **TAKEDA PHARMACEUTICAL COMPANY LIMITED**

1-1, Doshomachi 4-chome, Chuo-ku
Osaka-shi, Osaka 541-0045 Japan

having been assigned its right, title and interest in the invention by virtue of an Assignment recorded at the U.S. Patent and Trademark Office on September 28, 2015, at Reel 036666, Frame 0508

hereby sells, assigns and transfers to

ASSIGNEE: **SCOHIA PHARMA, Inc.**

26-1, Muraoka-Higashi 2-chome
Fujisawa-shi, Kanagawa 251-8555 Japan

and the successors, assigns and legal representatives of the ASSIGNEE


its entire right, title and interest in

U.S. Patent No. 10,087,229, issued October 2, 2018, entitled PEPTIDE COMPOUND

The ASSIGNOR hereby covenants that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment;

The ASSIGNOR further covenants that ASSIGNEES will, upon their request, be provided with all pertinent facts and documents relating to said invention and said application and legal equivalents as may be known and accessible to ASSIGNOR and will testify as to the same in any proceeding related thereto, and that ASSIGNOR will promptly execute and deliver to ASSIGNEES or their legal representatives any and all papers, instruments or affidavits required to apply for, obtain, maintain, issue, and enforce said application, said invention, any Letters Patent resulting from said application, and said equivalents thereof which may be necessary or desirable to carry out the purpose thereof;

IN WITNESS WHEREOF, I/WE have hereunto set hand and seal this November 22, 2023
(Date of Signing)


Signature of authorized representative ASSIGNOR

Takuya ABE

IP Region Head, Japan

Witness name Yoko NII

Witness name Yuko URUSHIBARA

Witness signature 二井 幸子

Witness signature 宇部 裕子

Date November 22, 2023

Date November 22, 2023